SCHEMBL1700834

SCHEMBL1700834

O=CCOc1cccc(F)c1F

nearest known ligand 0.61

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CTSS P25774 3/20 0.61
CTSK P43235 3/20 0.61
CTSL P07711 2/20 0.61
SLC6A2 P23975 3/20 0.40
SLC6A4 P31645 3/20 0.40
SLC6A3 Q01959 2/20 0.40
HTR1A P08908 2/20 0.38
GRM2 Q14416 2/20 0.36
CES2 O00748 1/20 0.35
BCHE P06276 1/20 0.35
CES1 P23141 1/20 0.35
FFAR1 O14842 1/20 0.35
TRPA1 O75762 1/20 0.35
ALDH1A1 P00352 2/20 0.34
HPGD P15428 1/20 0.34
HTT P42858 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
CTSB P07858 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL249457 0.84 CTSS (0.60) CTSSCTSKCTSLALDH1A1HPGD
SCHEMBL5536242 0.81 CTSL (0.43) CTSSCTSKCTSLSLC6A2SLC6A4
SCHEMBL5460266 0.81 HTR2C (0.46) CTSSCTSKCTSLSLC6A2SLC6A4
SCHEMBL13313285 0.80 CTSS (0.42) CTSSCTSKCTSLSLC6A2SLC6A4
SCHEMBL21094502 0.79 CTSS (0.48) CTSSCTSKCTSLALDH1A1HPGD
SCHEMBL12835858 0.78 CTSL (0.40) CTSSCTSKCTSLSLC6A2SLC6A4
SCHEMBL1512481 0.78 CTSL (0.40) CTSSCTSKCTSLSLC6A2SLC6A4
SCHEMBL12316488 0.78 CTSS (0.45) CTSSCTSKCTSLSLC6A2SLC6A4
SCHEMBL1937167 0.77 CTSS (0.39) CTSSCTSKCTSLSLC6A2SLC6A4
SCHEMBL2181095 0.77 CTSS (0.39) CTSSCTSKCTSLSLC6A2SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240115649-A1 CASPASE INHIBITION TO ENHANCE REGENERATION AND REPAIR AFTER SKIN OR GUT INJURY AND TO TREAT BACTERIAL OR VIRAL INFECTIONS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2024-04-11 US claimed
EP-4531919-A1 METHOD OF TREATING VITILIGO WITH INTERFERON-GAMMA ANTIBODY Elixiron Immunotherapeutics (Hong Kong) Limited (HK) 2025-04-09 EP disclosed
WO-2023235830-A1 METHOD OF TREATING VITILIGO WITH INTERFERON-GAMMA ANTIBODY ELIXIRON IMMUNOTHERAPEUTICS (HONG KONG) (CN) 2023-12-07 WO disclosed
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed
EP-3049530-B1 METHOD FOR CELL-FREE PROTEIN SYNTHESIS IN THE PRESENCE OF A CASPASE INHIBITOR FRAUNHOFER GES FORSCHUNG (DE) 2022-06-22 EP disclosed
US-11225655-B2 Bi-functional complexes and methods for making and using such complexes NUEVOLUTION A/S (DK) 2022-01-18 US disclosed
EP-3540059-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES Nuevolution A/S (DK) 2019-09-18 EP disclosed
CN-109072193-A The composition and method of B cell genome editor 达纳-法伯癌症研究所有限公司 2018-12-21 CN disclosed
EP-2558577-B1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION AS (DK) 2018-12-12 EP disclosed
CN-106232106-A Particulate vaccine formulations for inducing innate and adaptive immunity 奥本大学 2016-12-14 CN disclosed
US-20130281324-A1 BI-FUNCTINAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2013-10-24 US disclosed
WO-2011137485-A1 MEDIA AND METHODS FOR CELL CULTURE SYDNEY IVF LIMITED (AU) 2011-11-10 WO disclosed
EP-0840614-A1 CALPAIN INHIBITORS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES SANOFI WINTHROP, INC. (US) 1998-05-13 EP disclosed
WO-1996041638-A1 CALPAIN INHIBITORS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES SANOFI WINTHROP, INC. (US) 1996-12-27 WO disclosed